Are Tanzanian patients attending public facilities or private retailers more likely to adhere to artemisinin-based combination therapy?

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Bruxvoort, Katia ^a   Kalolella, Admirabilis ^b   Cairns, Matthew ^a   Festo, Charles ^b   Kenani, Mitya ^b   Lyaruu, Peter ^b   Kachur, S Patrick ^c   Schellenberg, David ^a   Goodman, Catherine ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b IFAKARA HEALTH INSTITUTE   (Tanzania)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

ACT; ADDOs; Adherence; Malaria; Private sector; Public health facilities

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

AGE; ARTICLE; CHILD; CONTROLLED STUDY; DRUG COST; DRUG DISPENSING OUTLET; EDUCATIONAL STATUS; FEMALE; HEALTH CARE FACILITY; HELP SEEKING BEHAVIOR; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALARIA; MALE; PATIENT CARE; PATIENT COMPLIANCE; PUBLIC HEALTH FACILITY; SOCIAL STATUS; TANZANIA; TANZANIAN; ADOLESCENT; COMBINATION DRUG THERAPY; INFANT; NEWBORN; PRESCHOOL CHILD; PRIVATE SECTOR; PSYCHOLOGY; PUBLIC SECTOR; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADOLESCENT; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PATIENT COMPLIANCE; PRIVATE SECTOR; PUBLIC SECTOR; TANZANIA;

EID: 84928691768     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0602-x     Document Type: Article

References (37)

1. Barnes KI, Watkins WM, White NJ. Antimalarial dosing regimens and drug resistance. Trends Parasitol. 2008;24:127-34.
2. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol. 2010;8:272-80.
3. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, et al. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J. 2009;8:253.
4. Filmer D. Fever and its treatment among the more and less poor in sub-Saharan Africa. Health Policy Plan. 2005;20:337-46.
5. WHO. World Malaria Report. Geneva: World Health Organization; 2012.
6. McCombie SC. Self-treatment for malaria: the evidence and methodological issues. Health Policy Plan. 2002;17:333-44.
7. Williams HA, Jones CO. A critical review of behavioral issues related to malaria control in sub-Saharan Africa: what contributions have social scientists made? Soc Sci Med. 2004;59:501-23.
8. Littrell M, Gatakaa H, Evance I, Poyer S, Njogu J, Solomon T, et al. Monitoring fever treatment behaviour and equitable access to effective medicines in the context of initiatives to improve ACT access: baseline results and implications for programming in six African countries. Malar J. 2011;10:327.
9. Tougher S, Ye Y, Amuasi JH, Kourgueni IA, Thomson R, Goodman C, et al. Effect of the Affordable Medicines Facility-malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data. Lancet. 2012;380:1916-26.
10. Bruxvoort K, Goodman C, Kachur SP, Schellenberg D. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS ONE. 2014;9:e84555.
11. Banek K, Lalani M, Staedke SG, Chandramohan D. Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence. Malar J. 2014;13:7.
12. Alba S, Dillip A, Hetzel MW, Mayumana I, Mshana C, Makemba A, et al. Improvements in access to malaria treatment in Tanzania following community, retail sector and health facility interventions - a user perspective. Malar J. 2010;9:163.
13. Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, Allen E, et al. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med. 2005;2:e330.
14. Kangwana BP, Kedenge SV, Noor AM, Alegana VA, Nyandigisi AJ, Pandit J, et al. The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial. PLoS Med. 2011;8:e1000437.
15. Yeung S, Van Damme W, Socheat D, White NJ, Mills A. Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malar J. 2008;7:96.
16. Watsierah CA, Jura WG, Raballah E, Kaseje D, Abong'o B, Ouma C. Knowledge and behaviour as determinants of anti-malarial drug use in a peri-urban population from malaria holoendemic region of western Kenya. Malar J. 2011;10:99.
17. Onyango EO, Ayodo G, Watsierah CA, Were T, Okumu W, Anyona SB, et al. Factors associated with non-adherence to Artemisinin-based combination therapy (ACT) to malaria in a rural population from holoendemic region of western Kenya. BMC Infect Dis. 2012;12:143.
18. Cohen JL, Yavuz E, Morris A, Arkedis J, Sabot O. Do patients adhere to over-the-counter artemisinin combination therapy for malaria? Evidence from an intervention study in Uganda. Malar J. 2012;11:83.
19. Simba DO, Warsame M, Kakoko D, Mrango Z, Tomson G, Premji Z, et al. Who gets prompt access to artemisinin-based combination therapy? A prospective community-based study in children from rural Kilosa, Tanzania. PLoS One. 2010;5:e12104.
20. Njau JD, Goodman C, Kachur SP, Palmer N, Khatib RA, Abdulla S, et al. Fever treatment and household wealth: the challenge posed for rolling out combination therapy for malaria. Trop Med Int Health. 2006;11:299-313.
21. Kizito J, Kayendeke M, Nabirye C, Staedke SG, Chandler CI. Improving access to health care for malaria in Africa: a review of literature on what attracts patients. Malar J. 2012;11:55.
22. United Republic of Tanzania Ministry of Health and Social Welfare. National Guidelines for Diagnosis and Treatment of Malaria. In: Malaria Control Series 25. Dar es Salaam, Tanzania: National Malaria Control Program; 2011.
23. AMFm Independent Evaluation Team. Independent Evaluation of Phase 1 of the Affordable Medicines Facility - malaria (AMFm), Multi-Country Independent Evaluation Report: Final Report. Calverton, Maryland and London: ICF International and London School of Hygiene and Tropical Medicine; 2012.
24. Rutta E. Accredited drug dispensing ADDOs. In: Medicines in Health Systems: Advancing Access, Affordability, and Appropriate Use. Geneva: World Health Organization; 2014.
25. Rutta E, Senauer K, Johnson K, Adeya G, Mbwasi R, Liana J, et al. Creating a new class of pharmaceutical services provider for underserved areas: the Tanzania accredited drug dispensing outlet experience. Prog Community Health Partnersh. 2009;3:145-53.
26. Rutta E, Kibassa B, McKinnon B, Liana J, Mbwasi R, Mlaki W, et al. Increasing access to subsidized artemisinin-based combination therapy through accredited drug dispensing outlets in Tanzania. Health Res Policy Syst. 2011;9:22.
27. Cohen JL, Yadav P, Moucheraud C, Alphs S, Larson PS, Arkedis J, et al. Do price subsidies on artemisinin combination therapy for malaria increase household use? Evidence from a repeated cross-sectional study in remote regions of Tanzania. PLoS ONE. 2013;8:e70713.
28. National Bureau of Statistics (NBS) [Tanzania] and ICF Macro. Tanzania Demographic and Health Survey 2010. Dar es Salaam, Tanzania: NBS and ICF Macro; 2011.
29. Bruxvoort K, Kalolella A, Nchimbi H, Festo C, Taylor M, Thomson R, et al. Getting antimalarials on target: impact of national roll-out of malaria rapid diagnostic tests on health facility treatment in three regions of Tanzania. Trop Med Int Health. 2013;18:1269-82.
30. Briggs MA, Kalolella A, Bruxvoort K, Wiegand R, Lopez G, Festo C, et al. Prevalence of malaria parasitemia and purchase of artemisinin-based combination therapies (ACTs) among drug shop clients in two regions in Tanzania with ACT subsidies. PLoS ONE. 2014;9:e94074.
31. Bruxvoort K, Festo C, Kalolella A, Cairns M, Lyaruu P, Kenani M, et al. Cluster Randomized Trial of Text Message Reminders to Retail Staff in Tanzanian Drug Shops Dispensing Artemether-Lumefantrine: Effect on Dispenser Knowledge and Patient Adherence. Am J Trop Med Hyg. 2014;91:844-53.
32. Kachur SP, Khatib RA, Kaizer E, Fox SS, Abdulla SM, Bloland PB. Adherence to antimalarial combination therapy with sulfadoxine-pyrimethamine and artesunate in rural Tanzania. Am J Trop Med Hyg. 2004;71:715-22.
33. Simba DO, Kakoko D, Tomson G, Premji Z, Petzold M, Mahindi M, et al. Adherence to artemether/lumefantrine treatment in children under real-life situations in rural Tanzania. Trans R Soc Trop Med Hyg. 2012;106:3-9.
34. Kabanywanyi AM, Lengeler C, Kasim P, King'eng'ena S, Schlienger R, Mulure N, et al. Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. Malar J. 2010;9:48.
35. Minzi O, Maige S, Sasi P, Ngasala B. Adherence to artemether-lumefantrine drug combination: a rural community experience six years after change of malaria treatment policy in Tanzania. Malar J. 2014;13:267.
36. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;CD000011.
37. White NJ. Why is it that antimalarial drug treatments do not always work? Ann Trop Med Parasitol. 1998;92:449-58.